Manfred Windisch, Ph.D.

Personal information:

Degree, First name, Last name: Manfred Windisch, Ph.D.
E-mail: manfred.windisch@agora-pharmacuticals.com

Research focus:

  • Pharmacology
  • Electrophysiology
  • Effects of neurotrophic factors on nerve cells from peripheral and central nervous system
  • EEG changes induced by hypoxia/ischemia
  • Behavioral studies of age-related cognitive changes in rodents
  • Development of animal models of Alzheimer’s disease
  • Management, Leadership, Business development

Education:

  • Management training as a representative of pharmaceutical industry (since 1995)
  • Basic education in EEG, Brain mapping and Recording of evoked potentials, University of Jena, Jena, Germany (1992)
  • Special education in Tissue culturing of neuronal cells, Osaka, Japan (Fujimoto Pharmaceuticals) and Penzberg, Germany (Boehringer) (1989)
  • Special education in Electrophysiology (education in all modern techniques of extra- and intracellular recording), University of Freiburg, Freiburg, Germany (1988)
  • Ph.D. degree in Pharmacology, Karl-Franzens University Graz, Graz, Austria (1985)

Employment:

  • Consultant for Rodin Therapeutics for development of HDAC inhibitors against AD (since 2016)
  • Consultant for ImmunoChem Therapeutics for development of new compounds interfering with neuro-inflammation (since 2016)
  • Consultant for CiToxLAB (since 2015)
  • Consultant for ORPHIT for development of new anti-inflammatory compounds for treatment of neurodegenerative diseases; early preclinical development (since 2015)
  • Consultant for Neurimmune for development of a new monoclonal antibody for treatment of ALS (2015)
  • Director for clinical research at the International Clinical Research Centre (ICRC) in Brno, Czech Republic (2014-2015)
  • Consultant for Cognition Therapeutics - regulatory toxicology; clinical development; Phase 1 and Phase 2 (since 2014)
  • Consultant for Pharmatrophix - regulatory toxicology; clinical development; Phase 2a (since 2014)
  • Consultant for PsychoGenics - animal models of AD, PD and related disorders (since 2014)
  • Scientific Advisor of Yuma Therapeutics (since 2013)
  • Scientific Advisor of Avraham Pharmaceuticals (since 2013)
  • Consultant for HARLAN - toxicology and safety pharmacology (since 2013)
  • Consultant for QPS (2013-2014)
  • CEO of NeuroScios GmbH, consulting and clinical trial company (CRO) for drug development for CNS disorders, focus: Alzheimer’s disease (since 2013)
  • Global Head of Neuroscience and Global Head of Clinical Research at QPS (2012-2013)
  • Organization of a Phase 2 efficacy study of a drug for treatment of Alzheimer patients in Canada (1996-1997)
  • CEO at JSW LifeSciences GmbH in Graz, Graz, Austria (1992-2012)
  • Member of management (Vice President R&D) of EBEWE Pharmaceuticals, Ltd, Unterach, Austria and Managing Director Research at EBEWE Pharmaceuticals, Ltd, Research Initiative Graz, Austria (1992-1999)
  • Lecturer of Pharmacology, Karl-Franzens University Graz, Graz, Austria (1985-1995)
  • Head of the new neurobiology working group, Karl-Franzens University Graz, Graz, Austria (1983-1985)
  • Medical Representative for a large Austrian pharmaceutical company EBEWE Pharma/BASF Pharma, Austria (1981-1983)

H-index: 27 and more than 120 publication in journal with impact factor